An Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.
Amgen Inc.’s disclosure Wednesday of a large stake in Neumora Therapeutics Inc. indicates that the value of its investment in the biopharmaceutical company, which recently went public, has tripled.
The 13D said Amgen’s investment started with the purchase of preferred shares for about $110 million and the grant of certain exclusive license rights, which was announced by the company’s in October 2021. That means Amgen has spent about $140 million to acquire its Neumora stake. Based on Tuesday’s closing price $11.71 for Neumora’s stock, Amgen’s stake was worth $414.2 million, or 195.8% more than what the company spent.The stock closed its first day of trading on Sept. 15 at $16.25, or 4.4% below its IPO price. It closed as low as $10.13, or 40.4% below the IPO price, on Sept. 20 before bouncing over the past four sessions.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Amgen Could Get a Piece of the Obesity MarketAmgen has a couple of shots on goal to break into one of the biggest markets the pharmaceutical industry has ever seen.
Read more »
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trialPliant Therapeutics Inc. shares gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic...
Read more »
San Diego biotech will pay $200K after allegations of misleading claimsBiora Therapeutics made misleading claims regarding the costs of genetic testing services
Read more »
What’s at stake in an extended government shutdown this time aroundWhile even a short government shutdown isn’t great for an economy grappling with other meaningful headwinds, it won’t be enough to push the resilient U.S. economy into recession.
Read more »
Czech giant takes major stake in CoronadoCzech Republic-based Sev.en Global Investments has struck a deal to acquire a 51% interest in ASX-listed coal miner Coronado Global Resources from founding company The Energy & Minerals Group (EMG). No details of the transaction were released, but Coronado told shareholders this week that the acquisition was subject to customary closing conditions, including regulatory approvals in the US and Australia.
Read more »